Publications

1. Geyer H. Are America’s Schools Prepared for an Overdose? American School Board Journal (Accepted). 2024.
   
2. Dugani SB, Fischer KM, Schroeder DR, Geyer HL, Maniaci MJ, Paulson M, Croghan IT, Burton MC. Global well-being, anxiety, social isolation, and emotional support among hospitalists during COVID-19 and Mpox outbreaks. Hosp Pract (1995). 2023 Oct; 51 (4):211-218 Epub 2023 Aug 01
   View PubMed
3. Mueller JT, Geyer HD, Karimi S, Poterack KA, Seville MTA, Buckner Petty S, Tipton SM. Two masks can be worse than one: N95 respirator failure caused by an overlying face mask. Infect Control Hosp Epidemiol. 2023 Sep; 44 (9):1529-1531 Epub 2022 Dec 20
   View PubMed
4. Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, Fox S, Ailts I, Dueck AC, Geyer HL, Mesa RA, Dunn WG, Nadezhdin E, Curto-Garcia N, Green A, Wilkins B, Coppell J, Laurie J, Garg M, Ewing J, Knapper S, Crowe J, Chen F, Koutsavlis I, Godfrey A, Arami S, Drummond M, Byrne J, Clark F, Mead-Harvey C, Baxter EJ, McMullin MF, Mead AJ. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023 Jul 1; 41 (19):3534-3544 Epub 2023 May 01
   View PubMed
5. Puranik A, Lenehan PJ, O'Horo JC, Pawlowski C, Niesen MJM, Virk A, Swift MD, Kremers W, Venkatakrishnan AJ, Gordon JE, Geyer HL, Speicher LL, Soundararajan V, Badley AD. Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. PNAS Nexus. 2022 Jul; 1 (3):pgac082 Epub 2022 June 08
   View PubMed
6. Pawlowski C, Silvert E, O'Horo JC, Lenehan PJ, Challener D, Gnass E, Murugadoss K, Ross J, Speicher L, Geyer H, Venkatakrishnan AJ, Badley AD, Soundararajan V. SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes. PNAS Nexus. 2022 Jul; 1 (3):pgac071 Epub 2022 July 04
   View PubMed
7. Dugani SB, Fischer KM, Geyer HL, Maniaci MJ, Croghan IT, Burton MC. Psychologic wellness of PA, NP, and physician hospitalists during the COVID-19 pandemic. JAAPA. 2022 May 1; 35 (5):45-53
   View PubMed
8. Niesen MJM, Matson R, Puranik A, O'Horo JC, Pawlowski C, Vachon C, Challener D, Virk A, Swift M, Speicher L, Gordon J, Geyer H, Lenehan PJ, Venkatakrishnan AJ, Soundararajan V, Badley A. Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection. PNAS Nexus. 2022 May; 1 (2):pgac042 Epub 2022 Apr 28
   View PubMed
9. Puranik A, Lenehan PJ, O'Horo JC, Pawlowski C, Virk A, Swift MD, Kremers W, Venkatakrishnan AJ, Challener DW, Breeher L, Gordon JE, Geyer HL, Speicher LL, Soundararajan V, Badley AD. Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. PNAS Nexus. 2022 May; 1 (2):pgac058 Epub 2022 May 20
   View PubMed
10. Niesen MJM, Pawlowski C, O'Horo J, Challener DW, Silvert E, Donadio G, Lenehan PJ, Virk A, Swift MD, Speicher L, Gordon JE, Geyer H, Halamka J, Venkatakrishnan AJ, Soundararajan V, Badley AD. Three doses of COVID-19 mRNA vaccination are safe based on adverse events reported in electronic health records Journal of the American Medical Association (JAMA) Network Open. 2022.
    
11. Dugani SB, Fischer KM, Schroeder DR, Geyer HL, Maniaci MJ, Croghan IT, Kashani D, Burton MC. Wellness of hospitalists and hospital medicine advanced practice providers during the COVID-19 pandemic, 2020-2021. J Hosp Med. 2022 Apr; 17 (4):259-267 Epub 2022 Mar 24
    View PubMed
12. Niesen MJM, Pawlowski C, O'Horo JC, Challener DW, Silvert E, Donadio G, Lenehan PJ, Virk A, Swift MD, Speicher LL, Gordon JE, Geyer HL, Halamka JD, Venkatakrishnan AJ, Soundararajan V, Badley AD. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records. JAMA Netw Open. 2022 Apr 1; 5 (4):e227038 Epub 2022 Apr 01
    View PubMed
13. Win H, Russell S, Wertheim BC, Maizes V, Crocker R, Brooks AJ, Mesa R, Huberty J, Geyer H, Eckert R, Larsen A, Gowin K. Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study. JMIR Form Res. 2022 Mar 31; 6 (3):e33581
    View PubMed
14. Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-Garcia J, O'Horo JC, Virk A, Swift MD, Gordon JE, Speicher LL, Geyer HL, Kremers W, Halamka J, Badley AD, Venkatakrishnan AJ, Soundararajan V. Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. Med. 2022 Jan 14; 3 (1):28-41.e8 Epub 2021 Dec 11
    View PubMed
15. Dugani C, Fischer K, Croghan I, Maniaci M, Geyer H, Burton MC. Psychological Wellness of Advanced Practice Provider and Physician Hospitalists During the COVID-19 Pandemic. Journal of the American Academy of Physician Assistants [ACCEPTED FOR PUBLICATION]. 2022.
    
16. Breeher LE, Wolf ME, Geyer H, Brinker T, Tommaso C, Kohlnhofer S, Hainy C, Swift M. Work Absence Following COVID-19 Vaccination in a Cohort of Healthcare Personnel. J Occup Environ Med. 2022 Jan 1; 64 (1):6-9
    View PubMed
17. Dugani SB, Geyer HL, Maniaci MJ, Fischer KM, Croghan IT, Coons TJ, Canan EL, Burton MC. Hospitalist perspectives on barriers to recommend and potential benefit of the COVID-19 vaccine. Hosp Pract (1995). 2021 Oct; 49 (4):245-251 Epub 2021 Apr 21
    View PubMed
18. Christensen SF, Scherber RM, Mazza GL, Dueck AC, Brochmann N, Andersen CL, Hasselbalch HC, Mesa RA, Geyer HL. Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer. 2021 Jun 10; 21 (1):691 Epub 2021 June 10
    View PubMed
19. Carter RE, Theel ES, Breeher LE, Swift MD, Van Brunt NA, Smith WR, Blanchfield LL, Daugherty EA, Chapital AB, Matson KM, Bews KA, Johnson PW, Domnick RA, Joyce DE, Geyer HL, Granger D, Hilgart HR, Turgeon CT, Sanders KA, Matern D, Nassar A, Sampathkumar P, Hainy CM, Orford RR, Vachon CM, Didehban R, Morice WG, Ting HH, Williams AW, Gray RJ, Thielen KR, Farrugia G, Mayo Clinic Serology Screening Program Operations Team. Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical Center. Mayo Clin Proc. 2021 May; 96(5):1165-1174. Epub 2021 Mar 26.
    View PubMed
20. Geyer HL. A Musical Ode to HLH. ASH Clin News. 2021.
    
21. Zavaleta KW, Philpot LM, Cunningham JL, Gazelka HM, Geyer HL, Rismeyer DL, Stitz AM, Clements CM. Why we still prescribe so many opioids: A qualitative study on -barriers and facilitators to prescribing guideline implementation. J Opioid Manag. 2021 Mar-Apr; 17 (2):115-124
    View PubMed
22. Dugani SB, Geyer HL, Maniaci MJ, Fischer KM, Croghan IT, Burton C. Psychological wellness of internal medicine hospitalists during the COVID-19 pandemic. Hosp Pract (1995). 2021 Feb; 49(1):47-55. Epub 2020 Oct 22.
    View PubMed
23. Padrnos L, Scherber R, Geyer H, Langlais BT, Dueck AC, Kosiorek HE, Senyak Z, Clark M, Boxer M, Cotter M, Harrison C, Stonnington C, Geda Y, Mesa R. Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition. Cancer Med. 2020 Nov; 9(22):8301-8309. Epub 2020 Sep 25.
    View PubMed
24. Dugani SB, Geyer HL, Maniaci MJ, Burton MC. Perception of barriers to research among internal medicine physician hospitalists by career stage. Hosp Pract (1995). 2020 Oct; 48 (4):206-212 Epub 2020 June 30
    View PubMed
25. Dugani SB, Geyer HL, Maniaci MJ, Schenzel HA, Burton MC. Perspectives on and barriers to research among advanced practice provider and physician hospitalists. Nurse Pract. 2020 Sep; 45 (9):41-47
    View PubMed
26. Geyer HL, Gazelka H, Mesa R. How I treat pain in hematologic malignancies safely with opioid therapy. Blood. 2020 Jun 25; 135 (26):2354-2364
    View PubMed
27. Gazelka HM, Clements CM, Cunningham JL, Geyer HL, Lovely JK, Olson CL, Philpot LM, Porter SB, Witt TJ, Zavaleta KW, Habermann EB. An Institutional Approach to Managing the Opioid Crisis. Mayo Clin Proc. 2020 May; 95 (5):968-981 Epub 2020 Mar 11
    View PubMed
28. Sykora D, Traub SJ, Buras MR, Hodgson NR, Geyer HL. Increased Inpatient Length of Stay After Early Unplanned Transfer to Higher Levels of Care. Crit Care Explor. 2020 Apr; 2 (4):e0103 Epub 2020 Apr 29
    View PubMed
29. Palmer J, Kosiorek HE, Wolschke C, Fauble VDS, Butterfield R 3rd, Geyer H, Scherber RM, Dueck AC, Gathany A, Mesa RA, Kroger N. Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. Biol Blood Marrow Transplant. 2019 Nov; 25 (11):2267-2273 Epub 2019 July 06
    View PubMed
30. Mazza GL, Kunze KL, Langlais BT, Kosiorek HE, DeWees TA, Geyer HL, Scherber RM, Mesa RA, Dueck AC. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies. Leuk Lymphoma. 2019 Jul; 60(7):1789-1795. Epub 2019 Jan 17.
    View PubMed
31. Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey. Ann Hematol. 2019 May; 98 (5):1119-1125 Epub 2019 Jan 29
    View PubMed
32. Palmer J, Scherber R, Girardo M, Geyer H, Kosiorek H, Dueck A, Jain T, Mesa R. Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. Biol Blood Marrow Transplant. 2019 Feb; 25 (2):398-402 Epub 2018 Oct 04
    View PubMed
33. Langlais BT, Geyer H, Scherber R, Mesa RA, Dueck AC. Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma. 2019 Feb; 60(2):402-408. Epub 2018 Jul 22.
    View PubMed
34. Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Dohner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res. 2017 Dec; 63:34-40 Epub 2017 Oct 14
    View PubMed
35. Colby R, Geyer H. Amiodarone-induced pulmonary toxicity. JAAPA. 2017 Nov; 30 (11):23-26
    View PubMed
36. Dawson N, Burton MC, Hull B, Beliles G, Pritchard I, Trautman C, Ferry L, Doyon A, Colby R, Chuu A, Kung ST, Khang T, Durocher D, Buras M, Kosiorek H, Agrwal N, Sen A, Goss D, Geyer H. Relation of Telemetry Use and Mortality Risk, Hospital Length of Stay, and Readmission Rates in Patients With Respiratory Illness. Am J Cardiol. 2017 Oct 15; 120 (8):1416-1420 Epub 2017 July 25
    View PubMed
37. Geyer H, Mesa RA. Approach to MPN Symptom Assessment. Curr Hematol Malig Rep. 2017 Oct; 12 (5):381-388
    View PubMed
38. Parsons CE, Singh S, Geyer HL. A case of hypercalcaemia in an immunocompetent patient with Mycobacterium avium intracellulare. JRSM Open. 2017 Jul; 8 (7):2054270417716614 Epub 2017 July 06
    View PubMed
39. Scherber RM, Geyer HL, Dueck AC, Kosiorek HE, Finazzi G, Cavazzina R, Masciulli A, Scarano M, Vannucchi AM, Mesa RA, Barbui T. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. Leuk Lymphoma. 2017 Jun; 58 (6):1481-1487 Epub 2016 Nov 10
    View PubMed
40. Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Dohner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica. 2017 Jan; 102 (1):85-93 Epub 2016 Aug 18
    View PubMed
41. Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Cancer. 2016 Jun 15; 122 (12):1888-96 Epub 2016 Apr 12
    View PubMed
42. Will KK, Williams J, Hilton G, Wilson L, Geyer H. Perceived efficacy and utility of postgraduate physician assistant training programs. JAAPA. 2016 Mar; 29 (3):46-8
    View PubMed
43. Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, Geyer HL, McCallister A, Cotter M, Van Husen B, Harrison CN, Mesa RA. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016 Feb 1; 122 (3):477-85 Epub 2015 Dec 15
    View PubMed
44. Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. J Clin Oncol. 2016 Jan 10; 34: (2)151-9.
    View PubMed
45. Baumann C, Geyer H, Williams J. Percutaneous transesophageal gastrotubing in the treatment of malignant gastrointestinal obstructions Journal of American Academy of Physician Assistants. 2015 Oct; 28(10):1.
    
46. Bottner R, Geyer H. Eosinophilia as an initial manifestation of ulcerative colitis. Journal of the American Academy of Physician Assistants. 2015 Oct; 28(10):1.
    
47. Mesa RA, Scherber RM, Geyer HL. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leuk Lymphoma. 2015 Jul; 56 (7):1989-99 Epub 2015 Mar 17
    View PubMed
48. Radia D, Geyer HL. Management of symptoms in polycythemia vera and essential thrombocythemia patients. Hematology Am Soc Hematol Educ Program. 2015; 2015:340-8.
    View PubMed
49. Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. Mediators Inflamm. 2015; 2015:284706 Epub 2015 Oct 11
    View PubMed
50. Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15 (1):e1-5 Epub 2014 June 11
    View PubMed
51. Geyer HL, Mesa RA. Emerging drugs for the treatment of myelofibrosis. Expert Opin Emerg Drugs. 2015; 20: (4)663-78.
    View PubMed
52. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Hematology Am Soc Hematol Educ Program. 2014 Dec 5; 2014: (1)277-86.
    View PubMed
53. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014 Dec 4; 124(24):3529-37.
    View PubMed
54. Scherber RM, Geyer HL, Mesa RA. Quality of life in MPN comes of age as a therapeutic target. Curr Hematol Malig Rep. 2014 Dec; 9 (4):324-30
    View PubMed
55. Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014 Jun 12; 123 (24):3803-10 Epub 2014 Feb 19
    View PubMed
56. Geyer H, Mesa RA. Assessing disease burden in patients with classic MPNs. Best Pract Res Clin Haematol. 2014 Jun; 27(2):107-19. Epub 2014 Jul 18.
    View PubMed
57. Cannon K, Hartsell Z, Ivanov I, Charles J, Joshi H, Blair J, Geyer H. Perceptions of internal medicine residency program candidates on the use of simulation in the selection process. J Grad Med Educ. 2014 Jun; 6 (2):338-40
    View PubMed
58. Gowin K, Emanuel R, Geyer H, Mesa RA. The new landscape of therapy for myelofibrosis. Curr Hematol Malig Rep. 2013 Dec; 8 (4):325-32
    View PubMed
59. Hensley B, Geyer H, Mesa R. Polycythemia vera: current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 Apr; 14 (5):609-17
    View PubMed
60. Bollin KB, Geyer HL, Mesa RA. Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis. Expert Opinion on Orphan Drugs. 2013; 1(7):539-47.
    
61. Geyer HL, Mesa RA. JAK2 Inhibition: Current Roles in Myelofibrosis and Initial Lessons Learned from Mexico. Revista de Hematologica de Mexico. 2013 Jan-Mar; 14(1).
    
62. Tibes R, Bogenberger JM, Geyer HL, Mesa RA. JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opin Investig Drugs. 2012 Dec; 21(12):1755-74. Epub 2012 Sep 19.
    View PubMed
63. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20; 30 (33):4098-103 Epub 2012 Oct 15
    View PubMed
64. Geyer HL, et al. Prepare to Attack JAK: Managing Myeloproliferative Neoplasm Constitutional Symptoms. The International Journal of Targeted Therapies in Cancer. 2012 Nov:38-40.
    
65. Geyer HL, Tibes R, Mesa RA. JAK2 inhibitors and their impact in myeloproliferative neoplasms. Hematology. 2012 Apr; 17 Suppl 1:S129-32
    View PubMed
66. Geyer H, Karlin N, Palen B, Mesa R. Asian-variant intravascular lymphoma in the African race. Rare Tumors. 2012 Jan 2; 4 (1):e10 Epub 2012 Mar 19
    View PubMed
67. Geyer H, Mesa R. Myelofibrosis symptoms and management. Myeloid and Lymphoid Disorders in Practice. 2012; 6(3):3-5.
    
68. Geyer HL, Viggiano RW, Lacy MQ, Witzig TE, Leslie KO, Mikhael JR, Stewart K. Acute lung toxicity related to pomalidomide. Chest. 2011 Aug; 140: (2)529-533.
    View PubMed
69. Geyer HL, Viney J, Karlin N. Metastatic carcinoid presenting as a breast lesion. Curr Oncol. 2010 Nov; 17 (6):73-7
    View PubMed
70. Geyer HL, Karlin N. Extraskeletal myxoid chondrosarcoma of the heart and review of current literature. Curr Oncol. 2010 Oct; 17(5):58-62.
    View PubMed
71. Geyer H, Caracciolo G, Abe H, Wilansky S, Carerj S, Gentile F, Nesser HJ, Khandheria B, Narula J, Sengupta PP. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr. 2010 Apr; 23 (4):351-69; quiz 453-5
    View PubMed